Kalaris Therapeutics Reports Positive Initial Phase 1a Results for TH103 in Neovascular AMD

Reuters

Dec 18, 2025

Kalaris <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Positive Initial Phase 1a Results for TH103 in Neovascular <a href="https://laohu8.com/S/AMD">AMD</a>

Kalaris Therapeutics Inc. announced positive initial results from its Phase 1a single ascending dose trial of TH103, a fully humanized recombinant fusion protein targeting VEGF, in treatment-naïve patients with neovascular age-related macular degeneration (nAMD). The data showed a mean 10-letter gain in visual acuity and rapid, robust anatomic improvement at one month following a single injection. TH103 was generally well tolerated, and pharmacokinetic analysis indicated a 27 to 51-fold lower plasma Cmax compared to current leading agents, suggesting increased intraocular retention. The results were presented during a live webcast and conference call on December 17, 2025. Kalaris is continuing enrollment in an ongoing Phase 1b/2 multi-ascending dose study, with preliminary efficacy and safety data expected in the second half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalaris Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9604003) on December 17, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2592943510"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2592943510\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2592943510?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-18 05:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592943510","market":"nz","top_or_hot":-1,"title":"Kalaris Therapeutics Reports Positive Initial Phase 1a Results for TH103 in Neovascular AMD","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Kalaris <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Positive Initial Phase 1a Results for TH103 in Neovascular <a href=\"https://laohu8.com/S/AMD\">AMD</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/KLRS\">Kalaris Therapeutics Inc.</a> announced positive initial results from its Phase 1a single ascending dose trial of TH103, a fully humanized recombinant fusion protein targeting VEGF, in treatment-naïve patients with neovascular age-related macular degeneration (nAMD). The data showed a mean 10-letter gain in visual acuity and rapid, robust anatomic improvement at one month following a single injection. TH103 was generally well tolerated, and pharmacokinetic analysis indicated a 27 to 51-fold lower plasma Cmax compared to current leading agents, suggesting increased intraocular retention. The results were presented during a live webcast and conference call on December 17, 2025. Kalaris is continuing enrollment in an ongoing Phase 1b/2 multi-ascending dose study, with preliminary efficacy and safety data expected in the second half of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalaris Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9604003) on December 17, 2025, and is solely responsible for the information contained therein.</span></i>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kalaris Therapeutics Reports Positive Initial Phase 1a Results for TH103 in Neovascular AMD</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKalaris Therapeutics Reports Positive Initial Phase 1a Results for TH103 in Neovascular AMD\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-18 05:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Kalaris <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Positive Initial Phase 1a Results for TH103 in Neovascular <a href=\"https://laohu8.com/S/AMD\">AMD</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/KLRS\">Kalaris Therapeutics Inc.</a> announced positive initial results from its Phase 1a single ascending dose trial of TH103, a fully humanized recombinant fusion protein targeting VEGF, in treatment-naïve patients with neovascular age-related macular degeneration (nAMD). The data showed a mean 10-letter gain in visual acuity and rapid, robust anatomic improvement at one month following a single injection. TH103 was generally well tolerated, and pharmacokinetic analysis indicated a 27 to 51-fold lower plasma Cmax compared to current leading agents, suggesting increased intraocular retention. The results were presented during a live webcast and conference call on December 17, 2025. Kalaris is continuing enrollment in an ongoing Phase 1b/2 multi-ascending dose study, with preliminary efficacy and safety data expected in the second half of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalaris Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9604003) on December 17, 2025, and is solely responsible for the information contained therein.</span></i>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210149790.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD-H","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL89hgYB:1","article_id":"2592943510","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592943510","pubTimestamp":1766005274,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Kalaris Therapeutics Inc. announced positive initial results from its Phase 1a single ascending dose trial of TH103, a fully humanized recombinant fusion protein targeting VEGF, in treatment-nave patients with neovascular age-related macular degeneration . The data showed a mean 10-letter gain in visual acuity and rapid, robust anatomic improvement at one month following a single injection. TH103 was generally well tolerated, and pharmacokinetic analysis indicated a 27 to 51-fold lower plasma Cmax compared to current leading agents, suggesting increased intraocular retention. The results were presented during a live webcast and conference call on December 17, 2025. Kalaris is continuing enrollment in an ongoing Phase 1b/2 multi-ascending dose study, with preliminary efficacy and safety data expected in the second half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely inform","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","NDAQ":"纳斯达克OMX交易所","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","KLRS":"Kalaris Therapeutics Inc.","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4139":"生物科技","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD"},"translate_title":"Kalaris Therapeutics报告TH103治疗新生血管性AMD的初步1a期结果积极","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KLRS":0.9,"NDAQ":0.9},"content_text":"Kalaris Therapeutics Reports Positive Initial Phase 1a Results for TH103 in Neovascular AMD\n\n\nKalaris Therapeutics Inc. announced positive initial results from its Phase 1a single ascending dose trial of TH103, a fully humanized recombinant fusion protein targeting VEGF, in treatment-naïve patients with neovascular age-related macular degeneration (nAMD). The data showed a mean 10-letter gain in visual acuity and rapid, robust anatomic improvement at one month following a single injection. TH103 was generally well tolerated, and pharmacokinetic analysis indicated a 27 to 51-fold lower plasma Cmax compared to current leading agents, suggesting increased intraocular retention. The results were presented during a live webcast and conference call on December 17, 2025. Kalaris is continuing enrollment in an ongoing Phase 1b/2 multi-ascending dose study, with preliminary efficacy and safety data expected in the second half of 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalaris Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9604003) on December 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}